Current projects

  • Heart OMics in AGEing (HOMAGE): Validation of “omics”-identified biomarkers for the diagnosis and treatment of heart failure in the ageing population (7th Framework Programme of the European Commission).

  • LIPCAR-HF: Lipcar, a prognostic marker in heart failure with reduced ejection fraction (Joint Transnatial Call ERA-CVD 2016 H2020 and Instituto de Salud Carlos III).

  • Targeted LYmphatic and MIcrovessel Treatments in metabolic-DISease in HFpEF (LYMIT-DIS): (Joint Transnatial Call ERA-CVD 2016 H2020 and Instituto de Salud Carlos III).

  • Effect of an intensive lifestyle intervention on the atrial fibrillation substrate (National Institutes of Health, EE.UU).

  • Involvement of NADPAH oxidases in interstitial myocardial fibrosis in heart failure (Fondo de Investigaciones Sanitarias; Instituto de Salud Carlos III).

  • Role of myocardial fibrosis in chronic heart failure related to ageing. Potential diagnostic and therapeutic implications of the PCP/PCPE-1-LOX axis (Fondo de Investigaciones Sanitarias; Instituto de Salud Carlos III).

  • Role of interstitial myocardial fibrosis in cardiac toxicity associated to breast cancer treatment. Diagnostic and therapeutic implications (Fondo de Investigaciones Sanitarias; Instituto de Salud Carlos III).

  • Spanish Network for Biomedical Research Centres in Cardiovascular Diseases. Centro de Investigación Biomédica en red Cardiovascular (CIBERCV) (Instituto de Salud Carlos III).

  • Personalized Cardiorenal Medicine in Navarra (MINERVA) (I+D 2018-2020 Strategic projects; Government of Navarra).



"Studies with specific molecules directed against new molecular targets in order to develop new pharmacological interventions that prevent or reverse myocardial damage in heart failure.", Arantxa González, investigadora principal.

Contact

Contact:
Nerea Cano
Avda. Pío XII, 55
31008 Pamplona
España

(+34) 948 194 700 Ext. 3044
ncano@unav.es